Form 4: Sutro Biopharma Director Granted Stock Options

Sutro Biopharma director Heidi Hunter received a grant of 1,500 stock options with an exercise price of $10.38, vesting monthly over six months.

Summary

• Heidi Hunter, a Director of Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
• The options have an exercise price of $10.38 per share.
• The grant date for these options was December 23, 2025.
• The options will vest monthly at a rate of 16.67% of the total award, contingent on continued service.
• The first vesting tranche is scheduled for January 23, 2026.
• The options have an expiration date of December 23, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine stock option grant to a director, which is a standard compensation practice. It's slightly positive as it aligns director incentives with shareholder value, but not significantly impactful on its own.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value creation.
• The vesting schedule incentivizes continued service and commitment from the director.

Risks

• The value of the stock options is subject to the future performance of Sutro Biopharma's common stock.
• The options will only have intrinsic value if the stock price exceeds the exercise price of $10.38.

Future Outlook

The stock options granted to Director Heidi Hunter are structured to vest monthly over approximately six months, with the first tranche vesting on January 23, 2026, and the full award vesting by June 23, 2026, assuming continued service. This provides a long-term incentive for the director through the option's expiration in December 2035.

Management Comments

• The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across many public companies. It serves as a key component of executive and director compensation packages, aiming to align the interests of leadership with those of shareholders by providing an incentive for long-term company performance and stock price appreciation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Companies such as Amgen, Gilead Sciences, and Biogen frequently utilize equity grants, including stock options and restricted stock units, to compensate their non-employee directors and executives.
• The vesting schedule, typically over several years or tied to continued service, is also standard, designed to promote long-term commitment and performance.
• The specific number of options (1,500) and exercise price ($10.38) would need to be compared against peer companies' director compensation disclosures to assess if it's above, below, or in line with industry averages for a company of Sutro Biopharma's size and stage. Without that specific peer data, it's noted as a common practice.

Corporate Governance

Related Party Transactions

• The stock option grant to Heidi Hunter, a director of Sutro Biopharma, Inc., constitutes a transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with long-term shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management/Directors: The grant provides a significant incentive for the director to remain with the company and contribute to its success.

Next Steps

• The stock options will begin vesting on January 23, 2026, with subsequent monthly vesting tranches.
• Heidi Hunter will continue to serve as a Director of Sutro Biopharma, Inc.

Key Dates

Keywords

Sutro Biopharma, STRO, Stock Option, Director Compensation, SEC Form 4, Equity Grant, Heidi Hunter, Biopharma